01

TRANQUILLO 2: Ritlecitinib Posts 21.86% F-VASI75 in Vitiligo

Ritlecitinib 100 mg drove a 21.86% F-VASI75 response at week 52 in the phase 3 TRANQUILLO 2 trial of nonsegmental vitiligo, against 2.40% on placebo. Pfizer plans FDA and EMA filings.